Summary

Overview
Global Nasal Polyposis Drugs Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX % during the forecast period 2023-2030.
Nasal polyposis are painless growths inside the sinuses, which are the hollow spaces inside the face's bones, or the nose. Nor are nasal polyposis cancer. Small nasal polyposis may not show any symptoms at all. Nasal polyposis in groups or larger growths can block the nose. They may result in infections, difficulty breathing, and loss of smell. Everyone can develop nasal polyposis. But young and middle-aged adults are more likely to develop these nasal polyposis.
Medications frequently reduce or eliminate nasal polyposis. But to get rid of them might require surgery. Nasal polyposis frequently recur even after being treated. Nasal polyposis are associated with sinus and nose swelling and irritation that lasts longer than 12 weeks. This condition is also known as inflammation. Chronic sinusitis is the issue going on inside. But nasal polyposis do not indicate a need for chronic sinusitis.
Market Dynamics: Drivers and Restraints
The rise of technological advancements
The diagnosis and management of nasal polyposis had been improved by developments in medical technology, such as less invasive surgical techniques, endoscopic treatments, and imaging technologies. These developments enhance patient outcomes while driving market expansion. For instance, Optinose stated on June 2, 2021, that the International Forum of Allergy & Rhinology's publication of a new stepped-care treatment algorithm, "Multidisciplinary consensus on a stepwise treatment algorithm for management of chronic rhinosinusitis with nasal polyposis," recommends Exhalation Delivery System-fluticasone (EDS-FLU) for the treatment of patients with nasal polyposis.
EDS-FLU is also advised as a step between initial treatment with conventional intranasal steroids and treatment escalation with surgery or biologic medications. Additionally, the increasing cost of healthcare, particularly in industrialised nations, enables increased investment in healthcare services and treatments, such as those for nasal polyposis.
New treatments are developed, researched, and adopted as a result of this financial backing. Nasal polyposis is a widespread disorder with a rising frequency around the globe. The number of persons affected by nasal polyposis is increasing, in part due to factors like rising pollution levels, higher allergen exposure, and changing lifestyles.
Market Dynamics: Restraint
The nasal polyposis market may experience limitations on expansion due to various causes. The creation, adoption, and marketing of medicines and treatments for this ailment may be hampered by several obstacles. For instance, nasal polyposis treatments can be expensive, particularly when it comes to procedures and ongoing drugs.
Patients may find this expense to be a substantial barrier to access, especially in areas with few insurance options and healthcare resources. Corticosteroids and immunosuppressive medications are two more treatments for nasal polyposis that may have unfavourable side effects. Patients and doctors may choose not to pursue particular treatment options due to safety concerns and possible adverse effects.
For more details of the report, Request for sample
Segment Analysis
The global nasal polyposis marketis segmented based on disease type, drug class, route of administration, distribution channel and region.
The corticosteroid segment from the disease type segment accounted for approximately 41.7% of nasal polyposis market
Due to the rising demand for corticosteroid treatment and its availability in a variety of dose forms, including injections, intranasal sprays, and drops depending on the patient's needs, the corticosteroid segment is expected to retain the largest market share. Additionally, several corticosteroids are readily available as topical preparations and aerosols that might shrink nasal polyposis. Additionally, the increase in product approvals also contributes to the segment's faster expansion.
For instance, July 29, 2021, US Food and Drug Administration (FDA) had approved Nucala (mepolizumab), a monoclonal antibody that blocks interleukin-5 (IL-5), as a treatment for people with chronic rhinosinusitis with nasal polyposis (CRSwNP), according to GlaxoSmithKline plc (GSK). The add-on maintenance treatment of CRSwNP in adult patients, 18 years of age and older, who have not responded adequately to nasal corticosteroids is the new indication for mepolizumab. Thus, all of those factors boost segment expansion.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
The nasal polyposis market as a whole is anticipated to be dominated by North America for the forecast period. This is mainly due to the rising prevalence of different malignancies and allergy diseases like asthma, sinusitis, and others. Research efforts in the United States, in addition to more regulatory agency approvals, are expected to fuel the expansion of the nasal polyposis market.
For instance, on December 01, 2020, according to Novartis, the US Food and Drug Administration (FDA) had approved the company's supplemental Biologics Licence Application (sBLA) for Xolair (omalizumab) for the maintenance treatment of nasal polyposis in adult patients, 18 years of age and older, who have not responded adequately to nasal corticosteroids.
Additionally, due to the frequency of allergic diseases and the pharmaceutical industry's consistent recent expansion, Asia Pacific is expected to increase at the most rapid pace during the forecast period. China is important in the region of Asia-Pacific because of its large population and extensive government activities in the healthcare field. Regional market expansion will be further boosted by further trials.
COVID-19 Impact Analysis
Due to COVID-19 symptoms associated with nasal polyposis, such as loss of smell, the COVID-19 pandemic is anticipated to propel growth of the global market for nasal polyposis. For instance, chronic rhinosinusitis is a condition marked by persistent inflammation of the sinonasal mucosa and is phenotypically categorised as chronic rhinosinusitis with nasal polyposis, according to information published in the Elsevier Journal in June 2022.
Between 56 and 78% of people with chronic rhinosinusitis experience impairment. One of the frequent early symptoms of COVID-19 is olfactory loss without nasal congestion. Nearly all of the symptoms of COVID-19 illness and chronic rhinosinusitis are the same, including loss of smell. This has led to an increase in the demand for medications used to treat nasal polyposis, which is anticipated to fuel the expansion of the market for those medications worldwide.
Market Segmentation
By Disease Type
• Bilateral ethmoidal polyp
• Antrochoanal Polyp
By Drug Class
• Nasal Corticosteroids
o Fluticasone
o Mometasone
o Budesonide
o Beclomethasone
o Others
• Oral Corticosteroids
o Prednisone
o Prednisolone
• Antihistamines
o Cetirizine
o Loratadine
o Fexofenadine
o Others
• Leukotriene Modifiers
o Montelukast
o Zafirlukast
• Others
By Route of Administration
• Oral
• Parenteral
• Nasal
• Others
By Distribution Channel
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Mylan N.V., Intersect ENT Inc, GlaxoSmithKline PLC, Lupin, Sanofi S.A, Sun Pharmaceutical Industries Ltd, Anant Pharmaceuticals Pvt. Ltd., OptiNose US, Teva Pharmaceutical Industries Ltd., Merck & Co Inc and among others.
Key Developments
• In August 6, 2020, for the treatment of adults (18 years and older) with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) for whom therapy with INC does not provide adequate disease control, Novartis stated that the European Commission (EC) had approved Xolair (omalizumab) as an add-on therapy with intranasal corticosteroids (INC).
Why Purchase the Report?
• To visualize the global nasal polyposis market segmentation based on disease type, drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of nasal polyposis market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global nasal polyposis market report would provide approximately 69 tables, 69 figures and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Drug Class
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The rise of technological advancements
4.1.1.2. Increasing product approvals
4.2. Restraints
4.2.1.1. Expensive cost associated with the research and development
4.2.2. Opportunity
4.2.3. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Disease Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type
7.2. Bilateral ethmoidal polyp *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Antrochoanal Polyp
8. By Drug Class
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8.1.2. Market Attractiveness Index, By Drug Class
8.2. Nasal Corticosteroids *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Fluticasone
8.2.4. Mometasone
8.2.5. Budesonide
8.2.6. Beclomethasone
8.2.7. Others
8.3. Oral Corticosteroids
8.3.1. Prednisone
8.3.2. Prednisolone
8.4. Antihistamines
8.4.1. Cetirizine
8.4.2. Loratadine
8.4.3. Fexofenadine
8.4.4. Others
8.5. Leukotriene Modifiers
8.5.1. Montelukast
8.5.2. Zafirlukast
8.6. Others
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Parenteral
9.4. Nasal
9.5. Others
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Mylan N.V. *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Intersect ENT Inc
13.3. GlaxoSmithKline PLC
13.4. Lupin
13.5. Sanofi S.A
13.6. Sun Pharmaceutical Industries Ltd
13.7. Anant Pharmaceuticals Pvt. Ltd.
13.8. OptiNose US
13.9. Teva Pharmaceutical Industries Ltd.
13.10. Merck & Co Inc
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us